---
title: "Phathom Pharmaceuticals, Inc. (PHAT.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PHAT.US/overview.md"
symbol: "PHAT.US"
name: "Phathom Pharmaceuticals, Inc."
parent: "https://longbridge.com/en/quote/PHAT.US.md"
datetime: "2026-04-17T10:17:05.901Z"
locales:
  - [en](https://longbridge.com/en/quote/PHAT.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PHAT.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PHAT.US/overview.md)
---

# Phathom Pharmaceuticals, Inc. (PHAT.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Address | 100 Campus Drive, Suite 102, Florham Park, New Jersey, United States |
| Website | [www.phathompharma.com](https://www.phathompharma.com) |

## Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

## Key Executives

| Name | Title |
|------|-------|
| Steven L. Basta | CEO, President & Director |
| Michael F. Cola | Independent chairman of the Board |
| David A. Socks | Co-Founder |
| Azmi Nabulsi | Co-Founder |
| Sanjeev Narula | Chief Financial & Business Officer |
| Anne Marie Cook | Chief Legal Officer & Corporate Secretary |
| Heidi Kunz Fields | Independent Director |
| Asit Parikh | Independent Director |
| James Newman Topper | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Frazier Life Sciences Management, LP | 15.69% | 2025-12-31 |
| Medicxi Ventures (UK) LLP | 9.40% | 2025-12-31 |
| Millennium Management LLC | 5.26% | 2026-03-06 |
| BlackRock, Inc. | 4.48% | 2025-12-31 |
| Abingworth LLP | 4.40% | 2025-12-31 |
| Invesco Ltd. | 4.38% | 2025-12-31 |
| The Vanguard Group, Inc. | 4.00% | 2025-12-31 |
| Ensign Peak Advisors, Inc. | 2.96% | 2025-12-31 |
| New Enterprise Associates, Inc. | 2.47% | 2025-12-31 |
| 683 Capital Management, LLC | 2.25% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Pharmaceuticals | 175110000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Phathom Pharmaceuticals, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Pharmaceuticals",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 175110000 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**